kyvero
Market leaders

MYGN

Myriad Genetics, Inc. (MYGN)

Healthcare • Diagnostics & Research

StockNasdaqGSUnited StatesUS62855J1043

5.56 USD -2.11% today Updated 13 Nov 2026 16:26

Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by Myriad Genetics, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.

Price history

Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.

All time

Updated 13 Nov 2026 16:26. Information, not advice. Showing the last 12 months. Create a free account to see the whole history

Results

Next results 23 Feb 2027 in 102 days · 16:00 · estimate -0.24
Last results -0.11 vs -0.20 estimated 04 Nov 2026 · Beat +44.9%
Beat the estimate 9 of 12 2 missed · 1 in line
Average surprise +161.3% reported against the estimate, last 12 quarters

Earnings per share: estimate and reported

06 Nov 2023: estimate -0.08 06 Nov 2023: reported -0.03 11/23 27 Feb 2024: estimate 0.01 27 Feb 2024: reported 0.04 02/24 07 May 2024: estimate -0.11 07 May 2024: reported -0.01 05/24 06 Aug 2024: estimate -0.01 06 Aug 2024: reported 0.05 08/24 07 Nov 2024: estimate 0.02 07 Nov 2024: reported 0.06 11/24 24 Feb 2025: estimate 0.03 24 Feb 2025: reported 0.03 02/25 06 May 2025: estimate -0.05 06 May 2025: reported -0.03 05/25 05 Aug 2025: estimate -0.01 05 Aug 2025: reported 0.05 08/25 23 Feb 2026: estimate -0.02 23 Feb 2026: reported 0.04 02/26 05 May 2026: estimate -0.07 05 May 2026: reported -0.09 05/26 30 Jul 2026: estimate -0.06 30 Jul 2026: reported -0.25 07/26 04 Nov 2026: estimate -0.20 04 Nov 2026: reported -0.11 11/26

Estimate Reported: beat Reported: miss In line

Quarterly results

DateEPS estimateEPS reportedSurpriseResult
23 Feb 2027 16:00 -0.24 — — Upcoming
04 Nov 2026 16:00 -0.20 -0.11 +44.9% Beat
30 Jul 2026 16:00 -0.06 -0.25 -332.7% Miss
05 May 2026 16:00 -0.07 -0.09 -34.7% Miss
23 Feb 2026 16:00 -0.02 0.04 +348.3% Beat
03 Nov 2025 16:00 -0.01 — +100.0% —
05 Aug 2025 16:00 -0.01 0.05 +724.2% Beat
06 May 2025 16:00 -0.05 -0.03 +44.8% Beat
24 Feb 2025 16:00 0.03 0.03 -0.9% In line
07 Nov 2024 16:00 0.02 0.06 +211.0% Beat
06 Aug 2024 16:00 -0.01 0.05 +561.7% Beat
07 May 2024 16:00 -0.11 -0.01 +91.1% Beat
27 Feb 2024 16:00 0.01 0.04 +214.2% Beat
06 Nov 2023 16:00 -0.08 -0.03 +63.6% Beat
02 Aug 2023 20:00 -0.09 -0.08 +7.3% Beat
03 May 2023 16:00 -0.19 -0.21 -8.4% Miss
28 Feb 2023 16:00 -0.17 -0.12 +30.4% Beat
01 Nov 2022 09:00 -0.08 -0.19 -141.3% Miss
04 Aug 2022 07:00 0.02 0.04 +84.6% Beat
05 May 2022 09:00 -0.09 -0.03 +65.6% Beat
24 Feb 2022 09:00 -0.06 -0.02 +64.1% Beat
02 Nov 2021 08:00 -0.01 -0.02 -100.0% Miss
03 Aug 2021 07:00 -0.10 0.12 +214.3% Beat
03 May 2021 16:00 -0.15 -0.06 +59.1% Beat
23 Feb 2021 16:00 -0.23 -0.12 +47.8% Beat
05 May 2020 17:00 0.01 -0.08 -1,166.7% Miss
06 Feb 2020 16:00 0.29 0.23 -21.7% Miss
04 Nov 2019 16:00 0.31 0.08 -74.5% Miss
13 Aug 2019 16:00 0.48 0.41 -14.6% Miss
07 May 2019 16:00 0.43 0.46 +6.3% Beat
05 Feb 2019 16:00 0.39 0.38 -3.1% Miss
06 Nov 2018 16:00 0.31 0.43 +38.2% Beat
21 Aug 2018 16:00 0.33 0.38 +15.5% Beat
08 May 2018 06:00 0.27 0.31 +13.9% Beat
06 Feb 2018 16:00 0.24 0.31 +30.9% Beat
07 Nov 2017 16:00 0.21 0.26 +26.4% Beat
08 Aug 2017 16:00 0.26 0.30 +13.2% Beat
02 May 2017 16:00 0.24 0.27 +13.3% Beat
07 Feb 2017 16:00 0.24 0.26 +8.2% Beat
01 Nov 2016 16:00 0.25 0.23 -9.3% Miss
09 Aug 2016 16:00 0.37 0.32 -14.4% Miss
03 May 2016 16:00 0.38 0.41 +7.8% Beat
02 Feb 2016 16:00 0.41 0.45 +10.1% Beat
03 Nov 2015 16:00 0.35 0.41 +16.3% Beat
11 Aug 2015 16:00 0.41 0.41 -0.4% In line
05 May 2015 16:00 0.39 0.40 +1.4% Beat
03 Feb 2015 16:00 0.34 0.40 +16.0% Beat
04 Nov 2014 16:00 0.27 0.25 -6.5% Miss
12 Aug 2014 16:00 0.46 0.48 +3.7% Beat
06 May 2014 16:00 0.45 0.60 +32.0% Beat

Annual results · USD

YearRevenueChangeNet income Net marginEPSEPS changeFree cash flow
2025 824.5M -1.6% -365.9M -44.4% -3.95 -180.1% -25.6M
2024 837.6M +11.2% -127.3M -15.2% -1.41 +55.7% -38.4M
2023 753.2M +11.0% -263.3M -35.0% -3.18 -128.8% -184.2M
2022 678.4M — -112M -16.5% -1.39 — -151.6M

Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.

Prices by day, week and month

Price history in USD, by month
PeriodOpening priceHighLow Closing priceChangeVolumeDividend
Nov 2026 In progress 6.36 6.75 5.47 5.56 -12.44% 18,036,806
Oct 2026 4.28 6.77 3.95 6.35 +47.33% 66,891,600
Sep 2026 2.95 4.39 2.92 4.31 +33.85% 44,402,200
Aug 2026 2.92 3.33 2.74 3.22 +12.59% 43,692,300
Jul 2026 5.73 6.43 2.81 2.86 -49.91% 37,446,400
Jun 2026 4.02 6.04 3.99 5.71 +43.83% 36,661,600
May 2026 4.70 5.06 3.53 3.97 -16.42% 42,686,600
Apr 2026 4.53 5.36 4.31 4.75 +5.56% 20,951,400
Mar 2026 5.06 5.49 4.20 4.50 -2.39% 56,433,900
Feb 2026 5.51 5.71 4.10 4.61 -17.97% 28,351,900
51 older periods: create a free account to see the whole history

Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.

News

Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.

Key data

Previous close
5.68 USD
Market cap
544.8M
Last dividend
1.7500 USD · 01 Jul 2009
Exchange
NasdaqGS
Country
United States
Sector
Healthcare
Industry
Diagnostics & Research
Currency
USD

Dividends

Ex-dividend datePer share
01 Jul 20091.7500 USD
15 Jun 20091.7500 USD

Why this score

How the score is made up
Part of the scorePointsWhy
Business growth Yearly growth of revenue and of earnings per share. 11.2 / 25
  • Revenue growth of 6.7% a year
Quality Return on equity, net margin and how stable the margins are. 0.0 / 25
  • ROE of -40%
Financial strength Net debt against operating earnings, interest cover and free cash flow. 6.5 / 20
  • Free cash flow yield of 0.9%
Valuation Free cash flow yield and the P/E against its sector. 8.7 / 15
  • Price / sales 0.7: it has no profit to price yet
Analysts How far the analysts' average target is from today's price. 1.3 / 10
  • Analysts' target is -6% from the price
  • Score capped at 60: free cash flow was negative in two of the last three years
  • Thin interest cover: operating profit is only -6.5× the interest
  • The last full year was a loss

Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A). Warnings take 12 points off.

Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio. How the score works

Figures

Valuation
FigureValueReading Sector median
P/E (forward) -9.15× Weak 14.16×
Price / book 2.02× Fair 3.5×
Price / sales 0.68× Good 3.33×
EV / EBITDA -11.32× Weak 11.19×
Free cash flow yield 0.9% Weak 2.1%
Quality
FigureValueReading Sector median
Gross margin 68.3% Good 54.9%
Operating margin -19.7% Weak 5.8%
Net margin -16.1% Weak 1.2%
Return on equity -40.2% Weak 4.4%
Return on assets -10% Weak 2.7%
Growth
FigureValueReading Sector median
Revenue growth / year 6.7% Fair 10.1%
Financial health
FigureValueReading Sector median
Debt / equity 0.78× Good 0.4×
Interest cover -6.46× Weak 2.17×
Current ratio 1.98× Good 2.64×
Dividends
FigureValueReading Sector median
Payout of earnings 0% Weak 0%

The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.

Similar shares

Follow MYGN and get alerts

Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.

Start for free Log in